Summary in Plain Language
In August, the FDA approved a pancreatic cancer targeted drug developed by the American biotech company Revolution Medicines. In just one year, the company’s market value soared from $8 billion to $44.5 billion, making it the company with the highest valuation in the global KRAS cancer therapy market. Although Revolution Medicines was only the third company in the world to receive approval for a KRAS inhibitor, it received a market value several times that of its predecessors. The key reason for this is that the previous two companies focused on the much less common KRAS mutations associated with lung cancer, while Revolution Medicines tackled the core mutation in pancreatic cancer, which had remained untouched for the past 40 years. This meant they grabbed the “sweetest fruit” in the entire market. However, the current $44.5 billion valuation is essentially an “expectation check” from the market; whether this can be turned into real cash depends on several critical challenges that the company still needs to overcome.
---
Detailed Analysis
1. Why did the third drug to receive approval have a market value more than 100 times that of the first two?
Many people may wonder: Amgen developed the world’s first KRAS inhibitor in 2021, breaking a decades-long “undruggable” barrier in the industry. Why does Revolution Medicines have a smaller market value now? The reason is that the first two companies chose the “easiest but also least valuable target”: the G12C mutation, which accounts for only 8% of non-small cell lung cancer cases and 1%-2% of pancreatic cancer cases, meaning it is practically useless for 98% of pancreatic cancer patients. Pancreatic cancer, on the other hand, has a 90% prevalence of KRAS mutations and is the most dependent on this protein for development; the average survival rate for patients with this disease is just over one year, and no targeted drugs have significantly improved survival rates in the past 40 years. Although the market for pancreatic cancer was vast, no one was able to develop effective drugs. Amgen and Mirati demonstrated that the KRAS “lock” could be unlocked, but they only managed to open the smallest and least valuable “lock.” Revolution Medicines, however, unlocked the biggest and most challenging “lock” in pancreatic cancer, earning the market’s generous reward.
2. What unique approach did Revolution Medicines use to unlock this “unlocked” target?
Previous companies failed to develop drugs for pancreatic cancer’s G12D and G12V KRAS mutations not because of lack of effort, but because of a chemical barrier: the KRAS protein’s surface is extremely smooth, making it difficult for small molecules to bind to it. The G12C mutation had a small protrusion that allowed drugs to adhere, but the other mutations lacked this feature. Revolution Medicines took a different approach. Instead of trying to directly bind small molecules to KRAS, they found a naturally occurring protein in the body and attached a special small molecule to it. This attachment created a new protrusion on the protein that fit perfectly over the smooth surface of KRAS, blocking its ability to send signals to tumors. In essence, they used a “plasticine plug” that could block any type of KRAS mutation, effectively combining the effects of multiple drugs.
3. The $44.5 billion valuation is merely an expectation; actual sales are far from it
The current high valuation reflects market expectations and has little to do with Revolution Medicines’ actual revenue. Experts predict that the company’s annual sales this year will be only $100 million to $150 million, less than 0.5% of its valuation. Previous drugs in this class, such as Amgen’s and Mirati’s, had limited sales. The main reason for this is the significant side effects of these drugs, which many patients cannot tolerate. Revolution Medicines’ new drug also has serious side effects, including rashes, diarrhea, and interstitial pneumonia. Competitors, such as a Chinese company called AddCare, have developed drugs with similar efficacy but lower side effects. AstraZeneca has already invested $2 billion to acquire overseas rights to one of these competing drugs, indicating a shift towards a market strategy that focuses on better efficacy and fewer side effects. Revolution Medicines’ early advantage is narrowing rapidly.
4. Overcoming three critical challenges to turn the valuation into cash
To realize its high valuation, Revolution Medicines must overcome three major hurdles:
- Switching from second-line to first-line treatment: Its drug is currently approved for only patients with advanced pancreatic cancer who have tried all other treatments. It needs to prove that it is more effective than traditional chemotherapy for newly diagnosed patients. If it succeeds, market size could increase by 3-5 times; otherwise, its sales will remain limited to a small group of patients.
- Expanding indications: The drug is currently effective only for pancreatic cancer; it needs to show efficacy in other cancers with larger patient populations, such as lung and colorectal cancer. If this is achieved, market size could increase by more than ten times. Failure to expand indications would confine the company to the niche market of pancreatic cancer.
- Marketability: The drug’s price of $39,800 per month is unaffordable for most people. If health insurance companies reject full reimbursement, sales will plummet. The company’s decision to sell rights to markets with large populations, such as China and Southeast Asia, acknowledges its limited ability to expand globally. In the pharmaceutical industry, those who first prove a treatment’s effectiveness often do not profit significantly; it is usually those who later make the market accessible to a wider audience who reap the biggest gains. Revolution Medicines is just the first to target this highly profitable market, but whether it can actually capitalize on this opportunity remains to be seen.
In summary, Revolution Medicines has made a significant breakthrough, but it still faces many challenges before its high valuation can be realized.